These results revealed that the pre-treatment of activated chicken PBMCs with pembrolizumab can induce the blockage of PD-1 and PD-L1 interaction, which contributed to the reinvigoration of T cell’s effector functions against tumor cells. This evidence concerns the gene PDCD1 and neoplasm.